All filters
Slidesets
How to combine new treatments? Clinical approach | Marion Peters, MD
Presented at:
International Workshop on HBV Cure 2016
Slidesets
Current Status of HBV Therapy | Pietro Lampertico, MD, PhD
Presented at:
International Workshop on HBV Cure 2016
Slidesets
Why do we need new treatments and what is our definition of cure? | Harry Janssen, MD, PhD
Presented at:
International Workshop on HBV Cure 2016
Slidesets
How to combine new treatments? Scientific approach | Jordan Feld, MD, MPH
Presented at:
International Workshop on HBV Cure 2016
Slidesets
Virological Approach - Entry inhibition | Stephan Urban, PhD
Presented at:
International Workshop on HBV Cure 2016
Slidesets
Can Bariatric surgery convert a non-candidate to a candidate? - Julie Heimbachx, MD
Presented at:
Symposium on Key Issues in Liver Transplantation for NASH 2016
Slidesets
What is an acceptable BMI - Lee Kaplan, MD, PhD
Presented at:
Symposium on Key Issues in Liver Transplantation for NASH 2016
Slidesets
How should we optimize immunosuppression? - Kittie Wynne, MD, PhD
Presented at:
Symposium on Key Issues in Liver Transplantation for NASH 2016
Slidesets
Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers | M. Imperial
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis | R. Kempker
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA | S. Heysell
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. Guiastrennec
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. Aljayyoussi
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Lost in translation: learning from preclinical data | Gerry Davies
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. Hatley
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. Wicha
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. Rajoli
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSB
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection | H. Blumberg
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
High drug tolerance of Mycobacterium tuberculosis in caseum | J. Sarathy
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016